TAR-200 for BCG–Unresponsive High-Risk NMIBC CIS: 1-Year Durability, PROs

At the AUA 2025 Annual Meeting, Joseph Jacob, MD, MCR, SUNY Upstate Medical University, shares the latest 1-year durability and patient-reported outcomes related to TAR-200 for BCG-unresponsive high-risk NMIBC carcinoma in situ. Dr. Jacob explains how this data may redefine the standard of care, whether he believes TAR-200 monotherapy could be a viable bladder-sparing alternative, in what patient populations might it be most appropriate, and how he sees TAR-200 differentiating itself in terms of mechanism, durability, patient experience, and feasibility in clinical practice.